Drug Trial Radar · NCT00631566
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
Last checked: Nov 20, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
May 2007
Primary completion
May 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Infectious Diseases Clinical Research Program; National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research Program
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA colonization and infection. This study will also investigate the utility of decolonization procedures for clearance of MRSA carriage and prevention of MRSA infections. Finally, the molecular characteristics and the antimicrobial sensitivities of isolates in this population will be determined.
Conditions
- HIV Infections
- Staphylococcal Infections
Interventions
Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%Drug
BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649). pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration. Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.
PlaceboDrug
Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA ColonizationTime frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Naval Medical Center San Diego/Infectious Disease Division
San Diego, California
Walter Reed National Military Medical Center
Bethesda, Maryland
San Antonio Military Medical Center (BAMC/WHMC)
San Antonio, Texas
Naval Medical Center Portsmouth
Portsmouth, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.